EUR 1.11
(-11.15%)
Year | Total Assets | Total Assets Growth |
---|---|---|
2023 | 47.53 Million EUR | -3.55% |
2022 | 49.28 Million EUR | 1.51% |
2021 | 48.55 Million EUR | 260.03% |
2020 | 13.48 Million EUR | 78.92% |
2019 | 7.53 Million EUR | 4.12% |
2018 | 7.23 Million EUR | -37.97% |
2017 | 11.66 Million EUR | 17.93% |
2016 | 9.89 Million EUR | -14.35% |
2015 | 11.55 Million EUR | 23.47% |
2014 | 9.35 Million EUR | 18.36% |
2013 | 7.9 Million EUR | 22.18% |
2012 | 6.47 Million EUR | -51.14% |
2011 | 13.24 Million EUR | 21.0% |
2010 | 10.94 Million EUR | 138.87% |
2009 | 4.58 Million EUR | 0.0% |
Year | Total Assets | Total Assets Growth |
---|---|---|
2024 Q2 | 38.89 Million EUR | 0.0% |
2023 Q4 | 47.53 Million EUR | 0.0% |
2023 FY | 47.53 Million EUR | -3.55% |
2023 Q2 | 50.98 Million EUR | 0.0% |
2022 FY | 49.28 Million EUR | 1.51% |
2022 Q2 | 51.2 Million EUR | 0.0% |
2022 Q4 | 55.29 Million EUR | 0.0% |
2021 FY | 48.55 Million EUR | 260.03% |
2021 Q4 | 48.55 Million EUR | 0.0% |
2021 Q2 | 37.82 Million EUR | 0.0% |
2020 FY | 13.48 Million EUR | 78.92% |
2020 Q4 | 13.53 Million EUR | 0.0% |
2020 Q2 | 1.96 Million EUR | 0.0% |
2019 Q2 | 9.21 Million EUR | 0.0% |
2019 Q4 | 7.53 Million EUR | 0.0% |
2019 FY | 7.53 Million EUR | 4.12% |
2018 Q4 | 7.23 Million EUR | 0.0% |
2018 FY | 7.23 Million EUR | -37.97% |
2018 Q2 | 10.84 Million EUR | 0.0% |
2017 FY | 11.66 Million EUR | 17.93% |
2017 Q4 | 11.66 Million EUR | 0.0% |
2017 Q2 | 8.74 Million EUR | 0.0% |
2016 FY | 9.89 Million EUR | -14.35% |
2016 Q4 | 9.89 Million EUR | 0.0% |
2016 Q2 | 14.04 Million EUR | 0.0% |
2015 Q2 | 15.26 Million EUR | 0.0% |
2015 FY | 11.55 Million EUR | 23.47% |
2015 Q4 | 11.55 Million EUR | 0.0% |
2014 Q4 | 9.35 Million EUR | 0.0% |
2014 Q2 | 6.11 Million EUR | 0.0% |
2014 FY | 9.35 Million EUR | 18.36% |
2013 Q4 | 7.9 Million EUR | 0.0% |
2013 Q2 | 10.06 Million EUR | 0.0% |
2013 FY | 7.9 Million EUR | 22.18% |
2012 Q4 | 6.47 Million EUR | 0.0% |
2012 Q2 | 9.9 Million EUR | 0.0% |
2012 FY | 6.47 Million EUR | -51.14% |
2011 Q2 | 17.18 Million EUR | 0.0% |
2011 FY | 13.24 Million EUR | 21.0% |
2011 Q4 | 13.24 Million EUR | 0.0% |
2010 Q4 | 10.94 Million EUR | 0.0% |
2010 FY | 10.94 Million EUR | 138.87% |
2010 Q2 | 14.38 Million EUR | 0.0% |
2009 FY | 4.58 Million EUR | 0.0% |
Name | Total Assets | Total Assets Difference |
---|---|---|
ABIONYX Pharma SA | 14.71 Million EUR | -223.138% |
ABIVAX Société Anonyme | 327.06 Million EUR | 85.466% |
Adocia SA | 24.95 Million EUR | -90.47% |
Aelis Farma SA | 26.28 Million EUR | -80.867% |
Biophytis S.A. | 11.93 Million EUR | -298.237% |
Advicenne S.A. | 12.4 Million EUR | -283.119% |
genOway Société anonyme | 31.84 Million EUR | -49.278% |
IntegraGen SA | 8 Million EUR | -494.144% |
Medesis Pharma S.A. | 1.92 Million EUR | -2367.566% |
NFL Biosciences SA | 3.97 Million EUR | -1097.13% |
Plant Advanced Technologies SA | 14.91 Million EUR | -218.741% |
Quantum Genomics Société Anonyme | 3.74 Million EUR | -1168.655% |
Sensorion SA | 46.49 Million EUR | -2.236% |
Theranexus Société Anonyme | 7.23 Million EUR | -556.747% |
TME Pharma N.V. | 2.49 Million EUR | -1808.213% |
Valbiotis SA | 33.24 Million EUR | -42.967% |
TheraVet SA | 7.53 Million EUR | -530.905% |
Valerio Therapeutics Société anonyme | 35.27 Million EUR | -34.755% |
argenx SE | 4.11 Billion EUR | 98.844% |
BioSenic S.A. | 9.55 Million EUR | -397.265% |
Celyad Oncology SA | 16.28 Million EUR | -191.94% |
DBV Technologies S.A. | 165.65 Million USD | 71.305% |
Galapagos NV | 4.35 Billion EUR | 98.909% |
Genfit S.A. | 173.87 Million EUR | 72.662% |
GeNeuro SA | 6.31 Million EUR | -652.96% |
Hyloris Pharmaceuticals SA | 47.68 Million EUR | 0.309% |
Innate Pharma S.A. | 184.19 Million EUR | 74.194% |
Inventiva S.A. | 69.13 Million EUR | 31.249% |
MaaT Pharma SA | 42.93 Million EUR | -10.721% |
MedinCell S.A. | 36.94 Million EUR | -28.65% |
Nanobiotix S.A. | 93.89 Million EUR | 49.377% |
Onward Medical N.V. | 43.62 Million EUR | -8.95% |
Oryzon Genomics S.A. | 106.9 Million EUR | 55.535% |
OSE Immunotherapeutics SA | 81.9 Million EUR | 41.961% |
Oxurion NV | 6.55 Million EUR | -625.704% |
Pharming Group N.V. | 426.33 Million EUR | 88.851% |
Poxel S.A. | 4.82 Million EUR | -885.561% |
GenSight Biologics S.A. | 9.08 Million EUR | -423.094% |
Transgene SA | 45.21 Million EUR | -5.123% |
Financière de Tubize SA | 1.92 Billion EUR | 97.525% |
UCB SA | 15.53 Billion EUR | 99.694% |
Valneva SE | 469.39 Million EUR | 89.873% |
Vivoryon Therapeutics N.V. | 30.82 Million EUR | -54.185% |